AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16956917 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week treatment with peginterferon alpha-2a (180 mug/week) and weight-based ribavirin (1000-1200 mg/day)
Number of subjects: 150
Study 16956917 — intervention group
Group type: COMPARATOR
Intervention: 24-week treatment with peginterferon alpha-2a (180 mug/week) and weight-based ribavirin (1000-1200 mg/day)
Number of subjects: 150
Study 16956917 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week treatment with RVR
Number of subjects: 150
Study 16956917 — intervention group
Group type: COMPARATOR
Intervention: 24-week treatment with RVR
Number of subjects: 150
Study 16956917 — intervention group
Group type: COMPARATOR
Intervention: 24-week treatment
Number of subjects: 150
Study 15542934 — intervention group
Group type: EXPERIMENTAL
Intervention: E3/pravastatin (2 mg E3 and 10 mg pravastatin)
Number of subjects: 33
Study 15542934 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (10 mg)
Number of subjects: 33
Study 15542934 — intervention group
Group type: COMPARATOR
Intervention: E3 (2 mg)
Number of subjects: 33
Study 15542934 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 33
Study 12163293 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously burned skin flaps
Number of subjects: 74
Study 12163293 — intervention group
Group type: COMPARATOR
Intervention: Normal skin flaps
Number of subjects: 74
Study 9856958 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (40 mg BID)
Number of subjects: 0
Study 9856958 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt intake (10 mmol/d)
Number of subjects: 0
Study 9856958 — intervention group
Group type: COMPARATOR
Intervention: High salt intake (200 mmol/d)
Number of subjects: 0
Study 9856958 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt intake with ACE inhibition
Number of subjects: 0
Study 8568984 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (9-month diet-induced)
Number of subjects: 170
Study 8568984 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (9-month program)
Number of subjects: 170
Study 8568984 — intervention group
Group type: COMPARATOR
Intervention: Control group (weight-maintenance)
Number of subjects: 170
Study 2194052 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine aqueous gel with 3% glycyrrhetinic acid 3‐0 hemiphthalate disodium (GAHPh)
Number of subjects: 24
Study 2194052 — intervention group
Group type: COMPARATOR
Intervention: Plain 10% lidocaine aqueous gel without GAHPh
Number of subjects: 24
Study 393736 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantra meditation
Number of subjects: 80
Study 393736 — intervention group
Group type: COMPARATOR
Intervention: Antimeditation control
Number of subjects: 80
Study 393736 — intervention group
Group type: COMPARATOR
Intervention: Progressive-relaxation control
Number of subjects: 80
Study 393736 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 80
Study 31704436 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid Misuse Prevention Program (OMPP)
Number of subjects: 76
Study 31704436 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 76
Study 30819204 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Sports Resort intervention group
Number of subjects: 30
Study 30819204 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 27397584 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐SET (False Safety Behavior Elimination Therapy)
Number of subjects: 28
Study 27397584 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 28
Study 26201190 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT group (n = 34) received medication and 3 years of standardized allergen vaccine therapy
Number of subjects: 68
Study 26201190 — intervention group
Group type: COMPARATOR
Intervention: ST group (n = 34) received symptomatic therapy
Number of subjects: 68
Study 26201190 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT group (n = 34)
Number of subjects: 68
Study 23352749 — intervention group
Group type: EXPERIMENTAL
Intervention: 640 U alum‐adjuvant EV71 vaccine
Number of subjects: 1200
Study 23352749 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 U alum‐adjuvant EV71 vaccine
Number of subjects: 1200
Study 23352749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 23352749 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1200
Study 21502544 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 0
Study 21502544 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 0
Study 19304671 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 1207
Study 19304671 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 1207
Study 19304671 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1207
Study 16963472 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg/day
Number of subjects: 850
Study 16963472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 850
Study 15623060 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolok implants
Number of subjects: 39
Study 12536700 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV)
Number of subjects: 0
Study 12536700 — intervention group
Group type: COMPARATOR
Intervention: Conventional medicine
Number of subjects: 0
Study 9296421 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (30 mg, per os)
Number of subjects: 9
Study 9296421 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (60 mg, per os)
Number of subjects: 9
Study 9296421 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg, per os)
Number of subjects: 9
Study 9296421 — intervention group
Group type: COMPARATOR
Intervention: Morphine (10 mg/70 kg, intravenously)
Number of subjects: 9
Study 9296421 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 9
Study 8413069 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 3755412 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (4 mg, 2 tablets)
Number of subjects: 23
Study 3755412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 29871567 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpal tunnel decompression with tourniquet
Number of subjects: 73
Study 29871567 — intervention group
Group type: COMPARATOR
Intervention: Carpal tunnel decompression without tourniquet
Number of subjects: 73
Study 27997551 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional constipation among students
Number of subjects: 1662
Study 27997551 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of functional constipation
Number of subjects: 1662
Study 27997551 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of sex with functional constipation
Number of subjects: 1662
Study 24945482 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month preoperative course of aerobic physical training
Number of subjects: 0
Study 24945482 — intervention group
Group type: COMPARATOR
Intervention: No aerobic physical training (control group)
Number of subjects: 0
Study 21535163 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel containing monocaprin and doxycycline (MCD)
Number of subjects: 0
Study 21535163 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel containing only monocaprin
Number of subjects: 0
Study 21535163 — intervention group
Group type: COMPARATOR
Intervention: Placebo hydrogel
Number of subjects: 0
Study 20227891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative fentanyl administration
Number of subjects: 113
Study 20227891 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of mechanical ventilation
Number of subjects: 113
Study 20227891 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein levels
Number of subjects: 113
Study 18792652 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling with vicarious reinforcement condition (received 3 personal anecdotes)
Number of subjects: 132
Study 18792652 — intervention group
Group type: COMPARATOR
Intervention: Control condition (received a fact sheet about problem solving)
Number of subjects: 132
Study 17214049 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (3 capsules of 0.5 g ginger powder each)
Number of subjects: 60
Study 17214049 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 capsules)
Number of subjects: 60
Study 17214049 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger
Number of subjects: 60
Study 17214049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12615014 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer controlled dental anesthetic delivery system
Number of subjects: 0
Study 12615014 — intervention group
Group type: COMPARATOR
Intervention: Traditional method of anesthetic delivery
Number of subjects: 0
Study 11763940 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral‐B CrossAction toothbrush
Number of subjects: 700
Study 11763940 — intervention group
Group type: COMPARATOR
Intervention: Comparison brushes (seven leading manual brushes)
Number of subjects: 700
Study 8853725 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole therapy
Number of subjects: 56
Study 8853725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 56
Study 8853725 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol drinking
Number of subjects: 56
Study 8853725 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated CD8 lymphocyte counts
Number of subjects: 56
Study 8853725 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine and aciclovir therapy
Number of subjects: 56
Study 8853725 — intervention group
Group type: COMPARATOR
Intervention: Recreational drug use
Number of subjects: 56
Study 8853725 — intervention group
Group type: COMPARATOR
Intervention: Oral sexual practices
Number of subjects: 56
Study 8853725 — intervention group
Group type: COMPARATOR
Intervention: Changes in CD4 and total lymphocyte counts
Number of subjects: 56
Study 1537726 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) 1,000 mg intravenous injection
Number of subjects: 6
Study 1537726 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 6
Study 6594722 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocervical PGE2 gel (400 micrograms)
Number of subjects: 30
Study 6594722 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic PGE2 gel (400 or 800 micrograms)
Number of subjects: 30
Study 6594722 — intervention group
Group type: COMPARATOR
Intervention: Control (inactive gel)
Number of subjects: 30
Study 6594722 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic PGE2 group
Number of subjects: 30
Study 6594722 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocervical PGE2 group
Number of subjects: 30
Study 6594722 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 30704149 — intervention group
Group type: EXPERIMENTAL
Intervention: Website education cohort (n=19)
Number of subjects: 80
Study 30704149 — intervention group
Group type: COMPARATOR
Intervention: Paper education cohort (n=19)
Number of subjects: 80
Study 28625429 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated anesthesia carts
Number of subjects: 1066
Study 28625429 — intervention group
Group type: COMPARATOR
Intervention: Conventional manual carts
Number of subjects: 1066
Study 26501411 — intervention group
Group type: EXPERIMENTAL
Intervention: Treprostinil
Number of subjects: 541
Study 26501411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 541
Study 24102103 — intervention group
Group type: EXPERIMENTAL
Intervention: Humor therapy program with professional performers (ElderClowns) and trained facility staff (LaughterBosses) for a minimum of nine 2-hour sessions over 12 weeks.
Number of subjects: 0
Study 22433263 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor proficiency assessed using BOTMP-SF
Number of subjects: 232
Study 22433263 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor proficiency divided into quartiles
Number of subjects: 232
Study 19260050 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV‐C (10% caprylate/chromatography purified); administered every 3 weeks for up to 24 weeks
Number of subjects: 59
Study 19260050 — intervention group
Group type: COMPARATOR
Intervention: Placebo; administered every 3 weeks for up to 24 weeks
Number of subjects: 59
Study 17318006 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 0
Study 17318006 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy (PHT)
Number of subjects: 0
Study 15516697 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril plus verapamil (2 mg per day + 180 mg per day)
Number of subjects: 1204
Study 15516697 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (2 mg per day)
Number of subjects: 1204
Study 15516697 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg per day)
Number of subjects: 1204
Study 15516697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1204
Study 11205181 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-pMDI through a non-static spacer (Nebuhaler)
Number of subjects: 12
Study 11205181 — intervention group
Group type: COMPARATOR
Intervention: CFC-pMDI through a static spacer (Nebuhaler)
Number of subjects: 12
Study 9771862 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (260 nmol, approximately 4000 IU) daily for 14 days
Number of subjects: 72
Study 9771862 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D2 (260 nmol, approximately 4000 IU) daily for 14 days
Number of subjects: 72
Study 7921339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine 25 mg
Number of subjects: 55
Study 7921339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine 50 mg
Number of subjects: 55
Study 7921339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine 25 mg + 10 mg domperidone
Number of subjects: 55
Study 7921339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine 25 mg + 1 transdermal scopolamine patch
Number of subjects: 55
Study 7921339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 3378855 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg/die/os
Number of subjects: 20
Study 3378855 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 800 mg/die/os
Number of subjects: 20
Study 31474438 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality headset wear
Number of subjects: 20
Study 31474438 — intervention group
Group type: COMPARATOR
Intervention: Conventional desktop computer display use
Number of subjects: 20
Study 28730951 — intervention group
Group type: EXPERIMENTAL
Intervention: NCCT + computed tomography angiography + computed tomography perfusion
Number of subjects: 400
Study 28730951 — intervention group
Group type: COMPARATOR
Intervention: NCCT alone
Number of subjects: 400
Study 26276754 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1,700 mg once daily for 28 days
Number of subjects: 200
Study 24267729 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin
Number of subjects: 48
Study 24267729 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 48
Study 20167357 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of structure in the activity as a whole
Number of subjects: 398
Study 20167357 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing structure in five-minute intervals within the activity
Number of subjects: 398
Study 19595060 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrullinated collagen type II (Cit‐CII)
Number of subjects: 34
Study 19595060 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen type II (CII)
Number of subjects: 34
Study 19595060 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Cit‐CII antibody
Number of subjects: 34
Study 19595060 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CII antibody
Number of subjects: 34
Study 16234829 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink A (0.1% dairy fat, 2.2% total fat) with a meal
Number of subjects: 184
Study 16234829 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink A without a meal
Number of subjects: 184
Study 16234829 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink B (1.5% dairy fat, 3.3% total fat) with a meal
Number of subjects: 184
Study 16234829 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink B without a meal
Number of subjects: 184
Study 16234829 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink with a meal
Number of subjects: 184
Study 15659500 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose methotrexate (IDM) and high-dose cytarabine (HiDAC)
Number of subjects: 180
Study 15659500 — intervention group
Group type: COMPARATOR
Intervention: APO regimen (doxorubicin, vincristine, prednisone, 6-mercaptopurine, and methotrexate)
Number of subjects: 180
Study 11984212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering therapy (CLT) using pravastatin 10-20 mg per day for 3 years
Number of subjects: 373
Study 11984212 — intervention group
Group type: COMPARATOR
Intervention: Dietary intervention
Number of subjects: 373
Study 11984212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering therapy (CLT) using pravastatin
Number of subjects: 373
Study 9868971 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + Metformin (2.55 g daily in three divided doses, n = 24)
Number of subjects: 47
Study 9868971 — intervention group
Group type: COMPARATOR
Intervention: Moderate insulin dose increase (20% of baseline, n = 23)
Number of subjects: 47
Study 7613532 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 400 mg
Number of subjects: 0
Study 7613532 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 800 mg
Number of subjects: 0
Study 7613532 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate 100 mg
Number of subjects: 0
Study 7613532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2694713 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing (Comfeel Ulcus)
Number of subjects: 0
Study 2694713 — intervention group
Group type: COMPARATOR
Intervention: Wet saline gauze dressing
Number of subjects: 0
Study 822782 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% aluminum chloride
Number of subjects: 0
Study 822782 — intervention group
Group type: COMPARATOR
Intervention: Carbol-fuchsin solution
Number of subjects: 0
Study 822782 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum chlorohydrate
Number of subjects: 0
Study 822782 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum acetate
Number of subjects: 0
Study 822782 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum chloride
Number of subjects: 0
Study 31981833 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin with local anaesthetic (BTX)
Number of subjects: 80
Study 31981833 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic (LA) alone
Number of subjects: 80
Study 31729052 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonablative fractional laser therapy (FLT) followed by photodynamic therapy (PDT)
Number of subjects: 11
Study 31729052 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT) alone
Number of subjects: 11
Study 31729052 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined FLT-PDT treatment
Number of subjects: 11
Study 31340588 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (12-week community-based randomized controlled trial)
Number of subjects: 45
Study 27998950 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine Cool Mint
Number of subjects: 196
Study 27998950 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 196
Study 26258448 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety and depression
Number of subjects: 337
Study 26258448 — intervention group
Group type: EXPERIMENTAL
Intervention: General self-efficacy
Number of subjects: 337
Study 23391030 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% H2O2 and nitrogenous-titanium-dioxide with light activation (Group A)
Number of subjects: 87
Study 23391030 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% H2O2 with light activation (Group B)
Number of subjects: 87
Study 23391030 — intervention group
Group type: COMPARATOR
Intervention: 35% H2O2 without light activation (Group C)
Number of subjects: 87
Study 21703382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers' dietary intake of fruit (0.9 servings/day)
Number of subjects: 50
Study 21703382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers' dietary intake of cookies
Number of subjects: 50
Study 21703382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers' dietary intake of potato chips
Number of subjects: 50
Study 21703382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers' dietary intake of vegetables (2.2 servings/day)
Number of subjects: 50
Study 21703382 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's intake of ice cream, chocolate, or french fries
Number of subjects: 50
Study 19139433 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (B) 10 mg/kg every 14 days and Erlotinib (E) 150 mg orally daily, continuously, for 28-day cycles
Number of subjects: 40
Study 19139433 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (B) and Erlotinib (E)
Number of subjects: 40
Study 17110262 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy force (225 g)
Number of subjects: 54
Study 17110262 — intervention group
Group type: EXPERIMENTAL
Intervention: Light force (25 g)
Number of subjects: 54
Study 17110262 — intervention group
Group type: COMPARATOR
Intervention: Control force (0 g)
Number of subjects: 54
Study 14975482 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute total sleep deprivation (88 hours)
Number of subjects: 20
Study 14975482 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term partial sleep deprivation (4.2 hours of sleep for 10 days)
Number of subjects: 20